Clinical stage regenerative medicine company, SpinalCyte, now features research studies on its website outlining the potential benefits of fibroblast technology.
Five insights:
1. SpinalCyte's website will publish both company-sponsored and independent fibroblast research studies on its website. SpinanlCyte CEO Pete O'Heeron believes the company's technology is the "regenerative cell source of the future."
2. The company focuses on regrowth of the spinal disc utilizing human dermal fibroblasts, which hold "significant advantages over mesenchymal stem cells," according to Chief Scientific Officer, Thomas Ichim, MD.
3. An estimated 85 percent of people over the age of 50 have traces of degenerative disc disease and physicians perform over 1.3 million procedures to treat the disease annually.
4. A discectomy or spinal fusion are the most common treatments for patients with DDD.
5. CybroCell, the company's off-the-shelf allogenic HDF product for DDD treatment, showed in a clinical trial that patients injected with the cell had sustained improvement in pain relief and increased back mobility.